Pre-rather than co-application of vigabatrin increases the efficacy of tiagabine in hippocampal slices

Epilepsia

Volumn 43, Issue 12, 2002, Pages 1455-1461

  Köhling, Rüdiger ^a,c   König, Klaus ^a   Lücke, Anne ^a   Mayer, Thomas ^b   Wolf, Peter ^b   Speckmannc, Erwin Joseph ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b EPILEPSY CENTER BETHEL   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Aminobutyric acid (GABA); Pharmacodynamic interactions; Rational polytherapy; Tiagabine; Vigabatrin

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; MAGNESIUM ION; NEUROTRANSMITTER; TIAGABINE; VIGABATRIN;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ELECTRIC POTENTIAL; ENZYME INHIBITION; EPILEPTIC DISCHARGE; GUINEA PIG; HIPPOCAMPUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICONVULSANTS; CULTURE TECHNIQUES; DRUG SYNERGISM; EVOKED POTENTIALS; GAMMA-AMINOBUTYRIC ACID; GUINEA PIGS; HIPPOCAMPUS; KINDLING, NEUROLOGIC; MAGNESIUM; NIPECOTIC ACIDS; PREMEDICATION; VIGABATRIN;

EID: 0036893974     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2002.00802.x     Document Type: Article

References (56)

1. Bourgeois BFD. Problems of combination drug therapy in children. Epilepsia 1988;29:S20-4.
2. Lothman EW. Neurobiology as a basis for rational polypharmacy: Section overview for rational polypharmacy conference. In Homan RW, ed. Amsterdam: Elsevier, 1996:3-7.
3. Löscher W, Wauquier A. Use of animal models in developing guiding principles for polypharmacy in epilepsy. Ration Polypharm 1996;xx:61-5.
4. Bourgeois BFD, Dodson WE. Antiepileptic and neurotoxic interactions between antiepileptic drugs. In: Homan RW, ed. Rational Polypharmacology. Amsterdam: Elsevier, 1996:61-5.
5. Morris JC, Dodson WE, Hatlelid JM, et al. Phenytoin and carbamazepine, alone and in combination: Anticonvulsant and neurotoxic effects. Neurology 1987;37:1111-8.
6. Bourgeois BF, Wad N. Combined administration of carbamazepine and phenobarbital: Effect on anticonvulsant activity and neurotoxicity. Epilepsia 1988;29:482-7.
7. Löscher W, Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy: Comparison with MK-801 and carbamazepine. J Pharmacol Exp Ther 1991;256:432-40.
8. Gordon R, Gels M, Wichmann JK, et al. Interaction of felbamate with several other antiepileptic drugs against seizures induced by maximal electroshock in mice. Epilepsia 1993;34:367-71.
9. Zarnowski T, Kleinrok Z, Turski WA, et al. The competitive NMDA antagonist, D-CCP-ene, potentiates the anticonvulsant activity of conventional antiepileptics against maximal electroshock-induced seizure in mice. Neuropharmacology 1994;33:619-24.
10. De Sarro G, Nava F, Aguglia U, et al. Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Neuropharmacology 1996;35:153-8.
11. 2+ channel inhibitors in mice. Pharmacol Biochem Behav 1997;56:629-35.
12. Jung MJ, Palfreyman MG. Vigabatrin: Mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. New York: Raven Press, 1995:211-23.
13. Abdul-Ghani AS, Couthino-Netto J, Bradford HF. The action of gamma-vinyl-GABA and gamma-acetylenic-GABA on the resting and stimulated release of GABA in vivo. Brain Res 1980;191:471-81.
14. Löscher W. Effect of inhibitors of GABA-transaminase on the synthesis, binding, uptake, and metabolism of GABA. J Neurochem 1980;21:1603-8.
15. Gram L, Larsson OM, Johnson A, et al. Experimental studies of the influence of vigabatrin on the GABA system. Br J Pharmacol 1989;27:12-7.
16. Yee JM, Agulian S, Kocsis JD. Vigabatrin enhances promoted release of GABA in neonatal rat optic nerve. Epilepsy Res 1998; 29:195-200.
17. Eckstein-Ludewig U, Fei J, Schwarz W. Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs. Br J Pharmacol 1999; 128:92-102.
18. Fraser CM, Sills GJ, Butler E, et al. Effects of valproate, vigabatrin and tiagabine on GABA uptake into human astrocytes cultured from foetal and adult brain tissue. Epileptic Disord 1999;1:153-7.
19. Schousboe A, Larrson OM, Seiler N. Stereo-selective uptake of GABA-transaminase inhibitors gammavinyl GABA and gammaacetylenic. Neurochem Res 1986;11:1497-505.
20. During M, Mattson RH, Schreyer R, et al. The effect of tiagabine HCL on extracellular GABA levels in the human hippocampus. Epilepsia 1992;33:83.
21. Fink-Jensen A, Suzdak P, Swedberg MDB, et al. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extra-cellular brain levels of GABA in awake rats. Eur J Pharmacol 1992;220:197-201.
22. Braestrup C, Nielsen EB, Sonnewald U, et al. R-N-[4,4-bis(3- methyl-2-thienyl) but -3-en-1-yl)] nipecotic acids binds with high affinity to the brain γ-aminobutyric acid uptake carrier. J Neurochem 1990;54:639-47.
23. Østergaard L, Gram L, Dam M. Tiagabine: Mechanisms of Action. In: Levy RH, Mattson RH, Meldrum BS, eds. New York: Raven Press, 1995:xx-x.
24. Lücke A, Mußhoff U, Köhling R, et al. Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy. Br J Pharmacol 1998;124:370-6.
25. Pitkänen A, Nissinen J, Jolkkonen E, et al. Effects of vigabatrin treatment on status epilepticus-induced neuronal damage and mossy fiber sprouting in the rat hippocampus. Epilepsy Res 1999; 33:67-85.
26. Sabau A, Frahm C, Pfeiffer M, et al. Age-dependence of the anticonvulsant effects of the GABA uptake inhibitor tiagabine in vitro. Eur J Pharmacol 1999;383:259-66.
27. Sills GJ, Butler E, Thompson GG, et al. Vigabatrin and tiagabine are pharmacologically different drugs: A pre-clinical study. Seizure 1999;8:404-11.
28. Engel D, Endermann U, Frahm C, et al. Acute effects of gammavinyl-GABA on low-magnesium evoked epileptiform activity in vitro. Epilepsy Res 2000;40:99-107.
29. Musshoff U, Köhling R, Lücke A. et al. Vigabatrin reduces epileptiform activity in brain slices from pharmacoresistant epilepsy patients. Eur J Pharmacol 2000;401:167-72.
30. Elger CE, Bauer J, Scherrmann J, et al. Aggravation of focal epilepsy seizures by antiepileptic drugs. Epilepsia 1998;39:S15-8.
31. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
32. Knake S, Hamer HM, Schomburg U, et al. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 1999;8: 314-7.
33. Wong I, Lhatoo SD. Adverse reaction to new anticonvulsant drugs. Drug Saf 2000;23:35-56.
34. Thompson AM, West DC. N-methylaspartate receptors mediate epileptiform activity evoked in some, but not all, conditions in the rat hippocampus in vitro. Neuroscience 1986;19:1161-77.
35. Mody I, Lambert JDC, Heinemann U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J Neurophysiol 1987;57:869-88.
36. Tancredi V, Avoli M, Hwa GGC. Low magnesium epilepsy in rat hippocampal slices: Inhibitory postsynaptic potentials in the CA1 subfield. Neurosci Lett 1988;89:293-8.
37. Tancredi V, Hwa GGC, Zona C, et al. Low magnesium epileptogenesis in the rat hippocampal slice: Electrophysiological and pharmacological features., Brain Res 1990;511:280-90.
38. 2+ in rat hippocampal slices. J Physiol 1994;478:379-93.
39. Dreier JP, Heinemann U. Late low magnesium-induced epileptiform activity in rat entorhinal cortex slices become insensitive to anticonvulsant valproic acid. Neurosci Lett 1990; 119:68-70.
40. Whittington MA, Roger DT, Jefferys JGR. Erosion of inhibition contributes to the progression of low magnesium burst in rat hippocampal slices. J Physiol 1995;486:723-34.
41. Zhang CL, Dreier JP, Heinemann U. Paroxysmal epileptiform discharges in temporal lobe slices after prolonged exposure to low magnesium are resistant to clinically used anticonvulsants. Epilepsy Res 1995;20:105-11.
42. Sanchez-Alcaraz A, Quintana B, Rodriguez I, et al. Plasma concentrations of vigabatrin in epileptic patients. J Clin Pharmacol Ther 1996;21:393-8.
43. Gustavson LE, Boellner SW, Grannemann GR, et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997;48:1032-7.
44. Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997;38:445-51.
45. Wadman WJ, Nunes-Filipe CM. Gamma-vinyl-GABA Induced Changes in Excitability in Rat Hippocampal Slices. In: Speckmann E-J, Gutnick MJ, eds. München: Urban & Schwarzenberg, 1992:xx-x.
46. Jackson MF, Esplin B, Capek R. Reversal of the activitydependent suppression of GABA-mediated inhibition in hippocampal slices from gamma-vinyl GABA (vigabatrin)-pretreated rats. Neuropharmacology 2000;39:65-74.
47. Köhling R, Vreugdenhil M, Bracci E, et al. Ictal epileptiform activity is facilitated by hippocampal GABAA receptor-mediated oscillations. J Neurosci 2000;20:6820-9.
48. Lukasiuk K, Pitkänen A. GABA(A)-mediated toxicity of hippocampal neurons in vitro. J Neurochem 2000;74:2445-54.
49. Jackson MF, Dennis T, Esplin B, et al. Acute effects of gammavinyl GABA (vigabatrin) on hippocampal GABAergic inhibition in vitro. Brain Res 1994;651:85-91.
50. Schousboe A, Larsson OM, Wood JD, et al. Transport and metabolism of γ-aminobutyric acid in neurons and glia: Implications for epilepsy. Epilepsia 1983;25:531-8.
51. Wu Y, Wang W, Richerson GB. GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter. J Neurosci 2001;21: 2630-9.
52. Dalby NO. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 2000;39:2399-407.
53. Draguhn A, Heinemann U. Different mechanisms regulate IPSC kinetics in early postnatal and juvenile hippocampal granule cells. J Neurophysiol 1996;76:3983-93.
54. Jackson MF, Esplin B, Capek R. Inhibitory nature of tiagabineaugmented GABAA receptor-mediated depolarization responses in hippocampal pyramidal cells. J Neurophysiol 1999;81:1192-8.
55. Jackson MF, Esplin B, Capek R. Activity-dependent enhancement of hyperpolarizing and depolarizing gamma-aminobutyric acid (GABA) synaptic responses following inhibition of GABA uptake by tiagabine. Epilepsy Res 1999:37:25-36.
56. Pfeiffer M, Draguhn A, Meierkord H, et al. Effects of γ-aminobutyric acid (GABA) agonists and GABA uptake inhibitors on pharmacosensitive and pharmacoresistant epileptiform activity in vitro. Br J Pharmacol 1996; 119:569-77.